Unlike classic psychedelics, MDMA works by flooding the brain with positive neurotransmitters. This creates a state of psychological "permissiveness," allowing an individual to approach and re-examine traumatic memories from a new perspective, free from the typical fear response.

Contrary to expectations, neuroimaging shows psychedelics reduce total brain activity. However, they simultaneously increase connectivity between disparate brain regions that don't normally communicate. This "rewiring" is correlated with therapeutic outcomes, such as unpairing negative mood states from self-perception networks.

The core innovation of psychedelics isn't just the mechanism but the treatment paradigm. By offering a rapid, acute treatment that doesn't require chronic medication, they could allow patients to get better and return to their lives, avoiding long-term entanglement with the mental health system and reducing stigma.

Bryan Johnson explains that as we age, the brain's default mode network (the engine of self and ego) develops stiff, repetitive patterns, narrowing our experience of reality. Psychedelics, especially 5-MeO-DMT, work by powerfully dissolving or 'blasting clean' this network, restoring a more childlike, neuroplastic state.

Psychedelics may treat trauma by reducing activity in the brain's outer cortex (responsible for language, planning). This shifts consciousness to deeper regions like the insular cortex, allowing for profound insights and self-compassion without the usual cognitive filters of guilt and blame.

Psychedelics don't erase traumatic memories. Their therapeutic power comes from inducing a massive perspective shift, allowing the individual to view the same event through a completely new and less threatening lens. This insight suggests most psychological suffering is a perspective problem.

While research on psychedelics focuses on psychiatric uses like depression and PTSD, Dr. Andrew Weil argues their greatest potential may lie in physical healing. He has witnessed instantaneous reversals of lifelong physical patterns through these experiences.

A major risk in psychedelic therapy is that vulnerable patients may generate what feel like 'recovered memories' of trauma. Good clinical practice requires therapists to remain neutral on the memory's truthfulness, instead working with its symbolic or emotional content to avoid implanting false and damaging beliefs.

Current mental health drugs force a choice: slow-acting daily pills or rapid-acting treatments like Spravato that require frequent, life-disrupting clinic visits. Psychedelic therapies offer a new paradigm by combining rapid onset of efficacy with durability lasting weeks or months from a single dose.